Domainex was established by scientists from the Institute of Cancer Research, University College London and Birkbeck College, with seed funding from the Bloomsbury BioSeed Fund. The company works on cutting edge science to create fragments of protein molecules encoded by cancer causing genes, or those involved in viral infections which can then be targeted for drug development. The technology developed by Domainex will greatly assist the study of the 3D structures of protein molecules involved in cancer and viral infection. This will provide a greater understanding as to how these proteins work and lead to the identification of new therapeutic drugs.